Previous close | 160.56 |
Open | 165.49 |
Bid | 163.88 x 100 |
Ask | 164.94 x 100 |
Day's range | 161.38 - 168.46 |
52-week range | 126.97 - 246.82 |
Volume | |
Avg. volume | 212,996 |
Market cap | 18.169B |
Beta (5Y monthly) | 0.63 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
SAN MATEO, Calif., May 08, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced results from the first quarter 2024 and business highlights.
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., April 26, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, released its 2023 Responsible Business & Sustainability Report highlighting the Company’s strategy, the progress it has made towards existing goals, and how it intends to achieve its bold new targets.
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., April 24, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share research outcomes from its broad hematology and solid tumor portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 - June 4, 2024.